Skip to main content

Impact of Nitrosamine Contamination Recalls on Angiotensin-Receptor-Blocker (ARB) Utilization in the U.S., U.K., Canada, and Denmark

Basic Details
Date
Type
Presentation
Description

This poster examines the trends of Angiotensin-Receptor-Blocker (ARB) utilization and switching patterns in the U.S., Canada, and Denmark, before and after July 2018, when the first ARB (Valsartan) was recalled. It was presented at the 38th International Conference on Pharmacoepidemiology and Therapeutic Risk Management. 

Materials

Impact of Nitrosamine Contamination Recalls on Angiotensin-Receptor-Blocker (ARB) Utilization in the U.S., U.K., Canada, and Denmark

Information
Host

International Society for Pharmacoepidemiology

Related Assessment(s)
Quantitative Assessment of the Impact of Nitrosamine Contamination and Angiotensin Receptor Blockers (ARB) Recall on ARB Utilization: A Multinational Study
Sentinel Drug Analysis: Utilization of Valsartan: A Descriptive Analysis
Presenter(s)

Eworuke E., Shinde M., Hou L., Paterson M., Jensen P., Maro JC., Rai A., Scarnecchia D., Dinci P., Woronow D., Ghosh RE., Welburn S., Pottegård A., Platt RW., Lee H., Bradley MC.